CH696260A5 - Fulvestrant Formulierung. - Google Patents
Fulvestrant Formulierung. Download PDFInfo
- Publication number
- CH696260A5 CH696260A5 CH00029/01A CH292001A CH696260A5 CH 696260 A5 CH696260 A5 CH 696260A5 CH 00029/01 A CH00029/01 A CH 00029/01A CH 292001 A CH292001 A CH 292001A CH 696260 A5 CH696260 A5 CH 696260A5
- Authority
- CH
- Switzerland
- Prior art keywords
- pharmaceutically acceptable
- fulvestrant
- formulation
- pharmaceutical formulation
- less
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 95
- 238000009472 formulation Methods 0.000 title claims description 85
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title claims description 75
- 229960002258 fulvestrant Drugs 0.000 title claims description 69
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 36
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical group C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 23
- 239000004359 castor oil Substances 0.000 claims description 22
- 235000019438 castor oil Nutrition 0.000 claims description 22
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 22
- 229960002903 benzyl benzoate Drugs 0.000 claims description 18
- 239000003981 vehicle Substances 0.000 claims description 17
- 229940066675 ricinoleate Drugs 0.000 claims description 13
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 claims description 13
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 12
- 238000010255 intramuscular injection Methods 0.000 claims description 10
- 239000007927 intramuscular injection Substances 0.000 claims description 10
- 210000000481 breast Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 210000005000 reproductive tract Anatomy 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 229940074928 isopropyl myristate Drugs 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 229940075495 isopropyl palmitate Drugs 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 229940011871 estrogen Drugs 0.000 description 11
- 239000000262 estrogen Substances 0.000 description 11
- 230000003637 steroidlike Effects 0.000 description 9
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 230000001833 anti-estrogenic effect Effects 0.000 description 8
- 239000000328 estrogen antagonist Substances 0.000 description 8
- 230000002035 prolonged effect Effects 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 229940046836 anti-estrogen Drugs 0.000 description 7
- 102000015694 estrogen receptors Human genes 0.000 description 7
- 108010038795 estrogen receptors Proteins 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003759 ester based solvent Substances 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- -1 4,4,5,5,5-pentafluoropentylsulfinyl Chemical group 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 2
- 229960003656 ricinoleic acid Drugs 0.000 description 2
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000001836 utereotrophic effect Effects 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022079 Injection site irritation Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0000313.7A GB0000313D0 (en) | 2000-01-10 | 2000-01-10 | Formulation |
| GBGB0008837.7A GB0008837D0 (en) | 2000-01-10 | 2000-04-12 | Formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH696260A5 true CH696260A5 (de) | 2007-03-15 |
Family
ID=26243352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH00029/01A CH696260A5 (de) | 2000-01-10 | 2001-01-10 | Fulvestrant Formulierung. |
Country Status (41)
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| GB0116620D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| HUP0400115A3 (en) * | 2001-07-07 | 2005-11-28 | Astrazeneca Ab | Pharmaceutical composition for the intramuscular administration of fulvestrant |
| EP2316922B1 (en) * | 2002-05-24 | 2013-05-22 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
| TW200404552A (en) * | 2002-05-30 | 2004-04-01 | Akzo Nobel Nv | Self administered contraception |
| US20050152858A1 (en) * | 2003-07-11 | 2005-07-14 | Isp Investments Inc. | Solubilizing agents for active or functional organic compounds |
| TW200526684A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
| EP1623713A1 (en) * | 2004-07-09 | 2006-02-08 | Proskelia SAS | Cominations of pure anti-estrogen with aromatase inhibitors |
| BRPI0608777A2 (pt) * | 2005-04-15 | 2010-01-26 | Schering Corp | métodos para tratamento ou prevenção de cáncer, bem como uso de inibidores de igf1r na preparação de composições farmacêuticas |
| KR20080066926A (ko) * | 2005-09-26 | 2008-07-17 | 호스피라 오스트레일리아 피티와이 리미티드 | 풀베스트란트 제형 |
| RU2338538C1 (ru) * | 2007-02-09 | 2008-11-20 | Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова | Антигипотензивное средство |
| JP2011514349A (ja) | 2008-03-07 | 2011-05-06 | サイドース・エルエルシー | フルベストラント配合物 |
| GB0807605D0 (en) | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| AU2014200332B2 (en) * | 2008-04-28 | 2016-10-06 | Diurnal Limited | Lipid composition |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| MX2012014431A (es) | 2010-06-10 | 2013-02-26 | Aragon Pharmaceuticals Inc | Modulares del receptor de estrogenos y usos de los mismos. |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| EP2616078B1 (en) * | 2010-09-16 | 2019-12-25 | Shimoda Biotech (Pty) Ltd | Fulvestrant compositions and methods of use |
| CA2836831C (en) | 2011-05-20 | 2015-06-02 | Capital, Business Y Gestion De Finanzas S.L. | Pharmaceutical composition |
| CN102391341B (zh) * | 2011-08-09 | 2013-05-22 | 福建省微生物研究所 | 制备6,7-脱氢-17β-烃酰氧基诺龙的方法 |
| CN103070871B (zh) * | 2011-10-26 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 一种氟维司群的药物组合物 |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| MX357496B (es) | 2011-12-14 | 2018-07-11 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrógenos fluorados y sus usos. |
| PE20150099A1 (es) | 2011-12-16 | 2015-01-30 | Olema Pharmaceuticals Inc | Compuestos novedosos de benzopirano, composiciones y usos de los mismos |
| CN102600064A (zh) * | 2012-03-31 | 2012-07-25 | 西安力邦制药有限公司 | 氟维司群或其衍生物缓释制剂及其制备方法 |
| CN102600073B (zh) | 2012-03-31 | 2014-01-01 | 莱普德制药有限公司 | 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法 |
| US11179468B2 (en) | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
| ES2983451T3 (es) * | 2012-04-09 | 2024-10-23 | Eagle Pharmaceuticals Inc | Formulaciones de Fulvestrant |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014169462A1 (zh) | 2013-04-18 | 2014-10-23 | 西安力邦医药科技有限责任公司 | 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法 |
| WO2014195032A1 (en) | 2013-06-07 | 2014-12-11 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| CN104337761B (zh) * | 2013-08-07 | 2019-03-26 | 江苏豪森药业集团有限公司 | 氟维司群药物组合物 |
| EP3041512A4 (en) * | 2013-09-06 | 2017-05-10 | Ahmed, Salah U. | Fulvestrant compositions |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| EP3116497A2 (en) | 2014-03-13 | 2017-01-18 | F. Hoffmann-La Roche AG | Therapeutic combinations with estrogen receptor modulators |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
| NZ769496A (en) | 2014-12-18 | 2023-09-29 | Hoffmann La Roche | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| IL310489A (en) | 2015-10-01 | 2024-03-01 | Olema Pharmaceuticals Inc | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS AND COMPOSITIONS COMPRISING SAME FOR USE IN TREATING CANCER |
| US20180289721A1 (en) | 2015-10-13 | 2018-10-11 | Themis Medicare Limited | Fulvestrant compositions |
| HRP20221462T1 (hr) | 2015-12-09 | 2023-01-20 | The Board Of Trustees Of The University Of Illinois | Selektivni nishodni regulatori receptora estrogena na bazi benzotiofena |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| JP6682163B2 (ja) * | 2016-04-06 | 2020-04-15 | 富士フイルム株式会社 | 医薬組成物 |
| US9969732B2 (en) | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| IL285928B2 (en) | 2016-05-06 | 2025-06-01 | Eagle Pharmaceuticals Inc | Fulvestrant formulations and methods of their use |
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| JP6611932B2 (ja) * | 2016-05-31 | 2019-11-27 | 富士フイルム株式会社 | 医薬組成物 |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| US20170362228A1 (en) | 2016-06-16 | 2017-12-21 | Genentech, Inc. | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| CN109311876B (zh) * | 2016-06-16 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 杂芳基雌激素受体调节剂及其用途 |
| CN107789320B (zh) * | 2016-08-31 | 2021-06-22 | 鲁南制药集团股份有限公司 | 一种氟维司群缓释注射液及其制备工艺 |
| KR20200052349A (ko) | 2017-09-11 | 2020-05-14 | 아토사 테라퓨틱스, 인크. | 엔독시펜을 제조 및 사용하는 방법 |
| KR102670293B1 (ko) | 2017-11-08 | 2024-05-30 | 이글 파마슈티컬즈 인코포레이티드 | 풀베스트란트 제제 및 그의 사용 방법 |
| AU2018368731A1 (en) | 2017-11-16 | 2020-05-14 | Novartis Ag | Combination therapies |
| CN111465398A (zh) * | 2018-01-31 | 2020-07-28 | 富士胶片株式会社 | 注射用制剂的制造方法 |
| RU2684330C1 (ru) * | 2018-02-02 | 2019-04-08 | Закрытое Акционерное Общество "Биокад" | Композиции фулвестранта |
| EP3801553A4 (en) | 2018-05-24 | 2022-04-27 | Kashiv Biosciences, LLC | PRODRUGS OF FULVESTRANT |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN111035613A (zh) * | 2018-10-12 | 2020-04-21 | 江苏恒瑞医药股份有限公司 | 一种包含氟维司群的可注射的药物组合物及其制备方法 |
| BR112021008516A2 (pt) | 2018-11-01 | 2021-09-14 | Syros Pharmaceuticals, Inc. | Inibidores de quinase 7 dependente de ciclina (cdk 7) |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| ES2982474T3 (es) | 2019-02-15 | 2024-10-16 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos |
| UY38700A (es) | 2019-05-20 | 2020-12-31 | Novartis Ag | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso |
| US12201591B2 (en) | 2019-07-03 | 2025-01-21 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
| MX2022000279A (es) | 2019-07-07 | 2022-02-03 | Olema Pharmaceuticals Inc | Regimenes de antagonistas del receptor de estrogeno. |
| RU2722988C1 (ru) * | 2019-11-19 | 2020-06-05 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей |
| EP4074304A4 (en) * | 2019-12-11 | 2024-01-10 | Shanghai Bocimed Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20240042051A1 (en) | 2020-11-24 | 2024-02-08 | Francesca Rocchetti | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| PE20240225A1 (es) | 2020-11-24 | 2024-02-16 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos |
| AU2022218128A1 (en) | 2021-02-02 | 2023-08-17 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| KR20230094172A (ko) * | 2021-12-20 | 2023-06-27 | 주식회사 삼양홀딩스 | 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법 |
| US20250339547A1 (en) | 2022-05-20 | 2025-11-06 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| EP4525925A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2024189481A1 (en) | 2023-03-10 | 2024-09-19 | Novartis Ag | Panras inhibitor antibody-drug conjugates and methods of use thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025215536A1 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Macrocyclic panras inhibitors for the treatment of cancer |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB817241A (en) | 1957-08-21 | 1959-07-29 | Vismara Francesco Spa | Oily solutions for parenteral administration containing adreno-cortical hormones |
| FR6241E (fr) | 1905-04-19 | 1906-10-10 | Ktiengesellschaft | Système de refroidissement du piston des moteurs à explosions et des compresseurs |
| DE947335C (de) | 1954-10-19 | 1956-08-16 | Schering Ag | Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron |
| US2983649A (en) | 1957-10-15 | 1961-05-09 | Francesco Vismara Societa Per | Ricinoleic acid ester solutions of adreno-cortical hormones |
| GB1060632A (en) * | 1962-09-11 | 1967-03-08 | Olin Mathieson | Steroid compositions |
| US3164520A (en) * | 1962-10-29 | 1965-01-05 | Olin Mathieson | Injectable steroid compositions containing at least 75% benzyl benzoate |
| JPS4327327Y1 (enExample) | 1965-01-07 | 1968-11-12 | ||
| NL151903B (nl) | 1965-03-24 | 1977-01-17 | Schering Ag | Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat. |
| USRE28690E (en) * | 1965-05-05 | 1976-01-20 | Schering Aktiengesellschaft | 17α-Ethinyl-18-methyl-19-nortestosterone esters |
| GB1207571A (en) * | 1967-01-13 | 1970-10-07 | Takeda Chemical Industries Ltd | Injectable composition |
| SU549118A1 (ru) | 1973-04-02 | 1977-03-05 | Способ синхронизации половой охоты у циклирующих свиноматок | |
| SU676284A1 (ru) | 1975-06-26 | 1979-07-30 | Научно-Исследовательский Институт Животноводства | Способ синхронизации половой охоты у самок домашних животных |
| DE2548413A1 (de) | 1975-10-27 | 1977-04-28 | Schering Ag | Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion |
| US4048310A (en) | 1976-02-24 | 1977-09-13 | E. R. Squibb & Sons, Inc. | Topical steroid formulation in form of lotion or cream |
| US4048309A (en) | 1976-02-24 | 1977-09-13 | E. R. Squibb & Sons, Inc. | Topical steroid ointment formulations |
| NL7711916A (nl) | 1977-10-29 | 1979-05-02 | Akzo Nv | Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden. |
| FI65914C (fi) * | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| DE3708942A1 (de) | 1987-03-18 | 1988-09-29 | Schering Ag | 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3733478A1 (de) | 1987-10-01 | 1989-04-13 | Schering Ag | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
| EP0310542B1 (de) † | 1987-10-01 | 1994-06-08 | Schering Aktiengesellschaft | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren |
| GB8813353D0 (en) † | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
| JPH04327327A (ja) | 1991-04-25 | 1992-11-16 | Toyoda Gosei Co Ltd | スリーブとホースの加締め用ダイス |
| CN1102095A (zh) | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| ZA9510926B (en) * | 1994-12-23 | 1996-07-03 | Schering Ag | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| US20010006963A1 (en) | 1995-03-16 | 2001-07-05 | Ursula Lachnit-Fixson | Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women |
| DE19510861A1 (de) | 1995-03-16 | 1996-09-19 | Schering Ag | Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen |
| EP0760237A1 (en) | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
| GB9525194D0 (en) * | 1995-12-12 | 1996-02-07 | Zeneca Ltd | Pharmaceutical composition |
| JPH09208496A (ja) * | 1996-01-30 | 1997-08-12 | Takeda Chem Ind Ltd | Ｌｈ−ｒｈ拮抗物質含有組成物 |
| DE19613972A1 (de) | 1996-04-09 | 1997-10-16 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl |
| GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| KR980008226A (ko) | 1996-07-05 | 1998-04-30 | 다케다 쿠니오 | 시각기능장애의 예방 및 치료제 |
| JPH10203982A (ja) * | 1996-07-05 | 1998-08-04 | Takeda Chem Ind Ltd | 視機能障害の予防・治療剤 |
| DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE19638045A1 (de) | 1996-09-18 | 1998-03-19 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen |
| JPH10152438A (ja) * | 1996-11-22 | 1998-06-09 | Takeda Chem Ind Ltd | １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物 |
| US6191107B1 (en) | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
| JPH11158200A (ja) * | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | ヒト成長ホルモン・亜鉛複合体及びその用途 |
| HRP20000366B1 (en) | 1997-12-03 | 2009-08-31 | Merck & Co. Inc. | Long acting injectable formulations containing hydrogenated castor oil |
| AU777572B2 (en) | 1999-04-01 | 2004-10-21 | Board Of Regents, The University Of Texas System | Compositions and methods for treating lymphoma |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| JP4327327B2 (ja) | 2000-04-03 | 2009-09-09 | ロボテック株式会社 | 固定スプレー揺動装置 |
| HUP0400115A3 (en) | 2001-07-07 | 2005-11-28 | Astrazeneca Ab | Pharmaceutical composition for the intramuscular administration of fulvestrant |
| GB0912999D0 (en) | 2009-07-27 | 2009-09-02 | Astrazeneca Ab | Method-803 |
-
2000
- 2000-01-10 GB GBGB0000313.7A patent/GB0000313D0/en not_active Ceased
- 2000-04-12 GB GBGB0008837.7A patent/GB0008837D0/en not_active Ceased
-
2001
- 2001-01-08 PT PT101806677T patent/PT2266573E/pt unknown
- 2001-01-08 BR BRPI0107445-8A patent/BR0107445B1/pt active IP Right Grant
- 2001-01-08 ES ES01900186.6T patent/ES2248272T5/es not_active Expired - Lifetime
- 2001-01-08 HK HK03105241.3A patent/HK1052884B/zh not_active IP Right Cessation
- 2001-01-08 EP EP10180661.0A patent/EP2286818B1/en not_active Expired - Lifetime
- 2001-01-08 MX MXPA02006698A patent/MXPA02006698A/es active IP Right Grant
- 2001-01-08 SI SI200131044T patent/SI2266573T1/sl unknown
- 2001-01-08 JP JP2001551480A patent/JP3713237B2/ja not_active Expired - Lifetime
- 2001-01-08 AU AU23863/01A patent/AU762080B2/en not_active Expired
- 2001-01-08 GB GB0100407A patent/GB2359254B/en not_active Expired - Lifetime
- 2001-01-08 CA CA002351004A patent/CA2351004C/en not_active Expired - Fee Related
- 2001-01-08 EP EP10180667.7A patent/EP2266573B1/en not_active Expired - Lifetime
- 2001-01-08 DK DK01900186.6T patent/DK1250138T4/en active
- 2001-01-08 SI SI200130446T patent/SI1250138T2/sl unknown
- 2001-01-08 CN CNB018035469A patent/CN1222292C/zh not_active Ceased
- 2001-01-08 WO PCT/GB2001/000049 patent/WO2001051056A1/en not_active Ceased
- 2001-01-08 EE EEP200200387A patent/EE05421B1/xx unknown
- 2001-01-08 HU HU0204137A patent/HU230162B1/hu not_active IP Right Cessation
- 2001-01-08 KR KR1020027008855A patent/KR100802366B1/ko not_active Expired - Lifetime
- 2001-01-08 IL IL15023001A patent/IL150230A0/xx active IP Right Grant
- 2001-01-08 DE DE60114145.8T patent/DE60114145T3/de not_active Expired - Lifetime
- 2001-01-08 US US10/169,777 patent/US20030125387A1/en not_active Abandoned
- 2001-01-08 RU RU2002121507A patent/RU2263507C9/ru active
- 2001-01-08 EG EG20010017A patent/EG24074A/xx active
- 2001-01-08 CZ CZ2002-2384A patent/CZ304689B6/cs not_active IP Right Cessation
- 2001-01-08 ES ES10180667.7T patent/ES2543384T3/es not_active Expired - Lifetime
- 2001-01-08 DK DK10180667.7T patent/DK2266573T3/en active
- 2001-01-08 PL PL356030A patent/PL202525B1/pl unknown
- 2001-01-08 AT AT01900186T patent/ATE306928T1/de active
- 2001-01-08 SK SK984-2002A patent/SK287221B6/sk not_active IP Right Cessation
- 2001-01-08 HK HK03101532.0A patent/HK1049286B/en not_active IP Right Cessation
- 2001-01-08 EP EP05016921A patent/EP1669073A3/en not_active Withdrawn
- 2001-01-08 EP EP01900186.6A patent/EP1250138B2/en not_active Expired - Lifetime
- 2001-01-09 US US09/756,291 patent/US6774122B2/en not_active Expired - Lifetime
- 2001-01-09 PT PT102548A patent/PT102548A/pt not_active Application Discontinuation
- 2001-01-09 BE BE2001/0021A patent/BE1013477A3/fr not_active IP Right Cessation
- 2001-01-09 IT IT000005A patent/ITTO20010005A1/it unknown
- 2001-01-10 IT IT2001TO000008A patent/ITTO20010008A1/it unknown
- 2001-01-10 DE DE10100779A patent/DE10100779A1/de not_active Ceased
- 2001-01-10 MY MYPI20010107A patent/MY118583A/en unknown
- 2001-01-10 NL NL1017075A patent/NL1017075C2/nl not_active IP Right Cessation
- 2001-01-10 ES ES200100057A patent/ES2186517B2/es not_active Expired - Fee Related
- 2001-01-10 CO CO01001317A patent/CO5280206A1/es not_active Application Discontinuation
- 2001-01-10 AR ARP010100100A patent/AR027510A1/es not_active Application Discontinuation
- 2001-01-10 TW TW090100514A patent/TWI259086B/zh active
- 2001-01-10 FR FR0100248A patent/FR2803516B1/fr not_active Expired - Lifetime
- 2001-01-10 CH CH00029/01A patent/CH696260A5/de not_active IP Right Cessation
- 2001-08-01 UA UA2002086628A patent/UA75879C2/uk unknown
-
2002
- 2002-05-24 ZA ZA200204165A patent/ZA200204165B/xx unknown
- 2002-06-13 IL IL150230A patent/IL150230A/en unknown
- 2002-06-18 BG BG106833A patent/BG65776B1/bg unknown
- 2002-07-03 NO NO20023227A patent/NO336286B1/no not_active IP Right Cessation
- 2002-07-03 IS IS6454A patent/IS2932B/is unknown
-
2003
- 2003-10-23 JP JP2003362875A patent/JP2004107353A/ja not_active Ceased
-
2004
- 2004-06-22 US US10/872,784 patent/US7456160B2/en not_active Expired - Lifetime
-
2008
- 2008-10-15 US US12/285,887 patent/US8329680B2/en not_active Expired - Fee Related
-
2011
- 2011-06-20 JP JP2011135962A patent/JP2011190275A/ja active Pending
-
2012
- 2012-09-04 US US13/602,667 patent/US8466139B2/en not_active Expired - Fee Related
-
2015
- 2015-06-08 NO NO20150741A patent/NO337329B1/no not_active IP Right Cessation
- 2015-07-22 CY CY20151100648T patent/CY1116520T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60114145T3 (de) | Fulvestrant formulierung | |
| EP1295600B1 (de) | Arzneimittel auf Basis von Gestagenen zur dermalen Anwendung enthaltend Ascorbinsäure sowie deren Salze | |
| DE60223542T2 (de) | Zusammensetzung mit fulvestrant | |
| Evans et al. | Europäisches Patentamt | |
| HK1153393A (en) | Fulvestrant formulation | |
| HK1150021B (en) | Fulvestrant formulation | |
| SA01210722B1 (ar) | تكوين صيدلي يحتوي على فولفسترانت fulvestrant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PFA | Name/firm changed |
Owner name: ASTRAZENECA AB Free format text: ASTRAZENECA AB# #SE-151 85 SOEDERTAELJE (SE) -TRANSFER TO- ASTRAZENECA AB# #SE-151 85 SOEDERTAELJE (SE) |
|
| PCAR | Change of the address of the representative |
Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH) |
|
| PLX | Patent declared invalid from date of grant onwards |